Trial · NCT03191721
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical Attachment Level (CAL) at 24 months. | 24 months | Difference between groups for the change in Clinical Attachment Level (CAL) from baseline to 24 months. |
| Secondary | Probing Depth (PD) ≥ 5 mm. | Baseline, 3, 6, 12, 18, 24 months. | Number of sites with Probing Depth (PD) ≥ 5 mm, evaluated in all volunteers. |
| Secondary | PD ≥ 6 mm. | Baseline, 3, 6, 12, 18, 24 months. | Number of sites with PD ≥ 6 mm, evaluated in all volunteers. |
| Secondary | PD ≥ 7 mm. | Baseline, 3, 6, 12, 18, 24 months. | Number of sites with PD ≥ 7 mm, evaluated in all volunteers. |
| Secondary | Full-mouth PD. | Baseline, 3, 6, 12, 18, 24 months. | Mean of the PD evaluated in all the periodontal sites from all volunteers. |
| Secondary | Full-mouth CAL. | Baseline, 3, 6, 12, 18, 24 months. | Mean of the CAL evaluated in all the periodontal sites from all volunteers. |
| Secondary | Bleeding on Probing (BOP). | Baseline, 3, 6, 12, 18, 24 months. | Percentage of sites with bleeding on probing (BOP), evaluated in all volunteers. |
| Secondary | Plaque accumulation. | Baseline, 3, 6, 12, 18, 24 months. | Percentage of sites with plaque accumulation, evaluated in all volunteers. |
| Secondary | Marginal bleeding. | Baseline, 3, 6, 12, 18, 24 months. | Percentage of sites with marginal bleeding. |
| Secondary | Sites gaining CAL ≥ 2mm. | Baseline - 24 months. | Percentage of sites gaining ≥ 2mm of CAL. |
| Secondary | Sites loosing CAL ≥ 2mm | Baseline - 24 months. | Percentage of sites loosing ≥ 2mm of CAL |
| Secondary | Radiographic Bone Height | Baseline, 3, 6, 12, 18, 24 months. | Mean values of radiographic bone height |
| Secondary | BOP reduction | Baseline - 24 months. | Reduction in the percentage of sites exhibiting BOP. |
| Secondary | Adverse effects | 3, 6, 12, 18, 24 months. | Occurrence of nausea and irritability obtained through a questionnaire of adverse effects |
| Secondary | Proportions of periodontal pathogenic bacterial species. | Baseline, 3, 6, 12, 18, 24 months. | Proportions of periodontal pathogenic bacterial species in subgingival biofilm samples. |
| Secondary | Counts of periodontal pathogenic bacterial species. | Baseline, 3, 6, 12, 18, 24 months. | Proportions of periodontal pathogenic bacterial species in subgingival biofilm samples. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03191721/registered